Healthcare M&A and Valuation
News and Insights

In October 2025, ARCHIMED Diagnostics, the diagnostics-focused arm of global healthcare investment firm ARCHIMED, completed its acquisition of a 60% majority stake in ARK Diagnostics, Inc., a Fremont, California-based developer and manufacturer of specialty in vitro diagnostic (IVD) assays and tests, from South Korean specialty chemical company Soulbrain Holdings. The transaction values ARK at approximately $428 million enterprise value, with Soulbrain retaining a 40% minorit

On May 28, 2025, global alternative asset manager Brookfield Asset Management, alongside Caisse de dépôt et placement du Québec (CDPQ), announced the acquisition  of GTCR’s Antylia Scientific, a U.S.-based integrated provider of scientific research tools, laboratory services and specialty instruments serving biopharma, diagnostics and academic markets. Antylia’s platform combines branded products, custom solutions, and technical services that address complex laboratory needs

On August 28th, 2023, life sciences giant Danaher Corporation announced its acquisition of Abcam plc, a leading provider of research...

Bio-Techne Corporation, a developer and manufacturer of life science reagents and instruments,  announced it made an investment in Wilson...